Comorbid Hypertension in Cancer Patients Undergoing Treatment: A Perspective

Hypertension (HTN) is the most common comorbidity among cancer patients and it can also be a consequence of cancer therapy. The appropriate management of HTN results in avoiding the adverse cardiovascular events such as coronary heart disease, heart failure, stroke, end-stage renal failure, and overall mortality. A hospital-based cross-sectional study was conducted on 50 cancer patients undergoing treatment at Healthcare Global hospital during the period November 2024 to January 2025. Out of this initial cohort of 50 patients, a series of 10 cases with large variation in levels of blood pressure (BP) were recorded across six timeframes of treatment. This case series of 10 patients includes both new onset and old cases of HTN. For the initial cohort of 50 cancer patients, the mean or median measure of HTN is not an ideal statistic as they currently appear less extreme than when the abnormal values were not regressed. Among the 10 patients chosen from the initial 50, 3 patients had prior history of HTN and 4 patients were incident cases of HTN. Also, the anti-HTN treatment was revised or newly initiated for a total of 4 cancer patients. It is essential to assess BP at baseline (initiation of chemotherapy) and during subsequent visits to the clinic. The choice of anti-HTN drug depends on the pathophysiology, which in turn mandates the coalition between oncologists and cardiologists in achieving an adequate control of BP.